Research use only. The products described on this page are offered for laboratory research only. They are not FDA-approved drugs, dietary supplements, foods, or cosmetics, and they are not for human or veterinary use. This page is educational and does not provide medical advice, dosing guidance, treatment guidance, or instructions for use.
What are peptides?
Peptides are short chains of amino acids connected by peptide bonds. The National Human Genome Research Institute describes peptides as chains that are typically 2 to 50 amino acids long; longer chains are usually described as polypeptides, and proteins are made from one or more polypeptides. In research settings, peptides are studied because many biological signaling systems use peptide structures or peptide-like receptor interactions.
How to read peptide research
- Preclinical findings are not the same as approved medical use. Cell, animal, and early-stage studies can explain mechanisms, but they do not prove safety or effectiveness in people.
- Published studies can have different goals. Some evaluate mechanism, detection, pharmacology, or safety monitoring rather than consumer use.
- Research-use materials are not medicines. They are intended for qualified laboratory research only and should not be used for diagnosis, treatment, mitigation, prevention, or cure of disease.
Peptides we carry
BPC-157
BPC-157 is a synthetic pentadecapeptide discussed in research literature around tissue-repair models, gastrointestinal models, angiogenesis, collagen activity, and inflammatory pathways. Much of the literature is preclinical, so findings should be read as research context rather than proof of human clinical benefit.
- PubMed: BPC-157 and wound-healing research review
- PubMed: Injectable peptide therapy primer noting limits of human validation
CJC-1295 + Ipamorelin
CJC-1295 is a synthetic growth-hormone-releasing hormone analog studied for effects on growth hormone and IGF-1 signaling. Ipamorelin is described in PubMed as a selective growth hormone secretagogue. Research on this category focuses on endocrine signaling and growth-hormone-release pathways; this does not make the combination an approved therapy or a recommendation for use.
- PubMed: CJC-1295 and GH/IGF-1 signaling in healthy adults
- PubMed: Ipamorelin as a selective growth hormone secretagogue
- PubMed: Peptide therapy primer covering CJC-1295 and ipamorelin research context
GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper-binding tripeptide, also known as glycyl-L-histidyl-L-lysine copper. Research literature discusses tissue remodeling, skin biology, wound-healing models, collagen and elastin pathways, glycosaminoglycan synthesis, and gene-expression effects. These sources are included for research background only and are not instructions for topical, injectable, or other human use.
- PubMed: The human tri-peptide GHK and tissue remodeling
- PubMed: Regenerative and protective actions of GHK-Cu
- PubMed: The potential of GHK as an anti-aging peptide
Retatrutide
Retatrutide, also known as LY3437943, is a peptide-based triple receptor agonist studied for activity at GIP, GLP-1, and glucagon receptors. Published and ongoing clinical research evaluates metabolic outcomes in participants with obesity, overweight, or type 2 diabetes. The FDA has stated that retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Any Retatrutide material on this site is for laboratory research only.
- PubMed: Triple-hormone-receptor agonist Retatrutide for obesity
- ClinicalTrials.gov: Retatrutide study record NCT05929066
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Source list
- NIH/NHGRI peptide glossary
- PubMed: BPC-157 review
- PubMed: Injectable peptide therapy primer
- PubMed: CJC-1295 GH/IGF-1 study
- PubMed: Ipamorelin pharmacology
- PubMed: GHK and tissue remodeling
- PubMed: GHK-Cu regenerative and protective actions
- PubMed: GHK as an anti-aging peptide
- PubMed: Retatrutide clinical research
- ClinicalTrials.gov: Retatrutide study
- FDA unapproved GLP-1 drug concerns